Business Today: Latest Business News, India economy News, Stock Markets, Sensex, Mutual Funds and Indian Tax
Loading...
Search

Total 21 results found. Search for [ Indian Patent Appellate Board ]

Results 1 to 21 of 21
Reuters
Mumbai, September 7, 2015
Pfizer is reviewing its options for further action, a Mumbai-based company spokesman said in an emailed statement.


PTI
Mumbai, August 2, 2013
The Intellectual Property Appellate Board (IPAB) has revoked the patent granted to the British drug major GlaxoSmithKline Pharma for its breast cancer drug Tykerb.


E. Kumar Sharma
April 13, 2013
The Supreme Court decision on Glivec sets the tone for other patent disputes and puts global drugmakers on the back foot.


E. Kumar Sharma
April 1, 2013
The Supreme Court has dismissed the Swiss drugmaker's attempt to win patent protection for its cancer drug Glivec, a ruling that does not bode well for many big global pharma companies fighting intellectual property battles in India.


BT Online Bureau
Mumbai, April 1, 2013
Novartis India shares, under pressure through the day, recovered from the initial losses to close at Rs 587.95, down 1.81 per cent. They touched a one-year low intra-day.


E Kumar Sharma
April 1, 2013
The ruling could have serious implications for global pharmaceutical companies if other emerging countries adopt similar provisions in their patent law.


BT Online Bureau
New Delhi, April 1, 2013
The Intellectual Property Appellate Board had denied the patent right for the drug to Novartis in 2006. The Swiss pharma major had in 2009 taken its challenge against a law that bans patents on newer forms of known drugs to the Supreme Court.


E Kumar Sharma
March 28, 2013
Novartis and many companies see the final decision on Glivec, whose generic versions are currently sold in the Indian market, as a landmark judgment for it would bring clarity on the interpretation and implementation of the Indian Patents Act.


BT Online Bureau
March 7, 2013
Bayer AG  will approach the high court in Mumbai against a ruling by Intellectual Property Appellate Board that upheld the compulsory licence issued to India's Natco Pharma to make and sell a low-cost generic of the German drug major's patented cancer drug Nexavar.


Associated Press
New Delhi, March 5, 2013
The Intellectual Property Appellate Board has rejected Bayer AG's plea to stop Natco Pharma from producing a cheaper generic version of its patented cancer drug.


PTI
December 11, 2012
Indian Patents Office has revoked a patent for an asthma drug held by US-based Merck & Co following a challenge from domestic pharma firm Cipla.


www.businesstoday.in
December 11, 2012
Sir Richard Branson will still own more than half of Virgin Atlantic, which will continue to fly as a separate airline under its own name.


PTI
New Delhi, December 4, 2012
Novartis approached the apex court challenging the order of Chennai-based Intellectual Property Appellate Board (IPAB), which rejected its appeal against patent department's decision on Glivec.


BT Online Bureau
New Delhi, November 29, 2012
Intellectual Property Appellate Board (IPAB) has again turned down drug firm AstraZeneca's plea for a patent on the lung cancer drug Gefitinib.


E. Kumar Sharma
November 4, 2012
India's Intellectual Property Appellate Board has revoked the patent granted in India to F. Hoffmann-La Roche AG (Roche) for pegylated interferon alfa-2a, a medicine used to treat hepatitis C, citing lack of evidence that the drug was better than existing treatments available in the market.


Team BT
October 9, 2012
Of late, the heads of a number of regulatory bodies have been flexing their muscles in different ways, using the full extent of their powers in a manner their predecessors had never done.


PTI
Berlin, May 10, 2012
Bayer holds the patent for Nexavar till 2020 and it will \"vigorously defend its patent within the available legal framework\".


PTI
New Delhi, May 7, 2012
In March this year, India had invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation.


Dinesh C. Sharma
New Delhi, March 28, 2012
The landmark decision of the patent office to break the monopoly of Bayer in kidney and liver cancer drugs recently is already having a rippling effect.


Shamni Pande
August 6, 2009
It is a case that will make business houses far more vigilant about intellectual property rights issues: one man, armed with a patent of a supposed new technology, is preventing large consumer electronic firms from importing dual-SIM technology mobile phones into India.


PAGES 1 OF 2  12